Loading
Camizestrant / Breast Cancer, Early Breast Cancer / Letrozole · Phase 3 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
CAMBRIA-2 is an active Phase 3 randomized trial comparing the selective estrogen receptor degrader camizestrant to standard adjuvant endocrine therapy in ER+/HER2- early breast cancer. No efficacy or safety results have been posted to this registry record; the study is ongoing with a planned 7-year treatment duration and up to 14-year follow-up for the primary endpoint of invasive breast cancer-free survival.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Breast Cancer, Early Breast Cancer; age from 18 Years; to 130 Years. Intervention: Arm B: camizestrant ± abemaciclib. Compared with: Arm A: standard endocrine therapy of investigator´s choice… — Active Comparator. n = 5,511. 661 sites across 44 countries.
Planned enrollment: 5511 participants with ER+/HER2- early breast cancer at intermediate-high or high recurrence risk Primary endpoint: invasive breast cancer-free survival, assessed up to 14 years Planned treatment duration: 7 years in either arm
This is a registry record only; no efficacy, safety, or outcome data are reported.
Results from this trial, when available, will inform whether the selective estrogen receptor degrader camizestrant offers an advantage over standard endocrine therapy in the adjuvant setting. Clinicians should await outcome reporting before considering practice changes.
This is an active Phase 3 trial registration with no results posted; the study is ongoing and has not yet reported efficacy or safety outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Results from this trial, when available, will inform whether the selective estrogen receptor degrader camizestrant offers an advantage over standard endocrine therapy in the adjuvant setting. Clinicians should await outcome reporting before considering practice changes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Registry record from ClinicalTrials.gov (NCT05952557). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 5511 participants (ACTUAL). Conditions: Breast Cancer, Early Breast Cancer. Interventions: DRUG: Camizestrant; DRUG: Tamoxifen; DRUG: Anastrozole; DRUG: Letrozole; DRUG: Exemestane; DRUG: Abemaciclib. Primary outcome measures: Invasive breast cancer-free survival (IBCFS) , Up to 14 years. Brief summary: This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.